A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis
A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis have?
A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis has 261 citations in the OpenAlex counts ScholarIQ stores.
When was A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis published?
A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis has 2016 year in the ScholarIQ index.
What is the open-access status of A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis?
A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis has hybrid oa status in the ScholarIQ index.
What is the DOI of A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis?
The DOI for A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis is on the source record.
What is the PMID of A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis?
The PMID for A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis is on the source record.
What is the OpenAlex record for A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis?
The OpenAlex for A randomized phase 2b trial of baricitinib, an oral Janus kinase (<scp>JAK</scp>) 1/JAK2 inhibitor, in patients with moderate‐to‐severe psoriasis is on the source record.